The global anaplastic thyroid cancer drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Anaplastic thyroid cancer (ATC) is also known as anaplastic thyroid carcinoma. It is an aggressive variant of thyroid cancer that causes the uncontrolled growth of cells in the thyroid gland. The major factor contributing to the growth of the market is the increasing prevalence of thyroid cancer across the globe.
According to the American Society of Clinical Oncology (ASCO), in 2021, thyroid cancer is the seventh most common cancer with 3 times more likely to occur in women. Additionally, in 2021, an estimated 44,280 adults including 12,150 men and 32,130 women were diagnosed with thyroid cancer in the US with an estimated mortality rate of 2,200 mortalities including 1,050 men and 1,150 women from this disease. Furthermore, from 2009 to 2018, the mortality rate rose by over half a per cent annually. Hence, the rising prevalence of the disease is driving the demand for anaplastic thyroid cancer drugs, which in turn, is driving the growth of the market.
To Request a Sample of our Report on Anaplastic Thyroid Cancer Drug Market: https://www.omrglobal.com/request-sample/anaplastic-thyroid-cancer-drug-market
Some key players operating in the market include Novartis International AG, Pfizer Inc., and Daiichi Sankyo Company, Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in September 2021, Exelixis, Inc. announced the approval of cabozantinib (Cabometyx) from the US FDA. It is used for the treatment of locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are ineligible or refractory to radioactive iodine in adult and pediatric patients 12 years of age and older.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
Segment Covered-
- By Product
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape– Novartis International AG, Pfizer Inc., and Daiichi Sankyo Company, Ltd., among others.
(Get 15% Discount on Buying this Report)
A full Report of Anaplastic Thyroid Cancer Drug Market is Available @ https://www.omrglobal.com/industry-reports/anaplastic-thyroid-cancer-drug-market
Global Anaplastic Thyroid Cancer Drug Market Report by Segment
By Product
- Sorafenib
- Paclitaxel and Pazopanib HCl
- MLN0128
- Everolimus
- CA4 P
- Bevacizumab
- Others
Global Anaplastic Thyroid Cancer Drug Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
